Journal
CURRENT RHEUMATOLOGY REPORTS
Volume 14, Issue 6, Pages 516-525Publisher
SPRINGER
DOI: 10.1007/s11926-012-0296-9
Keywords
Systemic sclerosis; Scleroderma; Vasculopathy; Vasculitis; Angiogenesis; Vasculogenesis; Endothelial cells; ANCA
Categories
Funding
- United Therapeutics Corp.
- InterMune
- Boehringer Ingelheim
- Actelion Pharmaceuticals Ltd.
- Celgene Corp.
- Sigma-Tau Pharmaceuticals
- Pfizer
- Ergonex Pharma
- Sanofi-Aventis
Ask authors/readers for more resources
Systemic sclerosis (SSc) is a devastating and potentially life-threatening multi-organ system disease. SSc is marked by skin thickening and tightening, Raynaud's phenomenon and digital ischemia with ulceration, gastrointestinal dysmotility, cardiopulmonary involvement with pulmonary fibrosis and pulmonary arterial hypertension, as well as renal failure. Fibrosis is the most obvious manifestation of SSc. Vascular involvement and inflammation are other prominent components of SSc pathology, and both features are also seen in vasculitis. This review analyzes whether there is evidence for vasculitis especially with particular organ manifestations and subgroups of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available